Molecular basis of statin-associated myopathy

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Coronary artery disease (CAD) is a leading cause of death globally.
• Statins are primary drugs for lowering low-density lipoprotein cholesterol and preventing CAD.
• While effective, statins carry a risk of myotoxic side effects.

Purpose of the Study:

• To review the molecular pathogenesis of statin-induced myopathy.
• To elucidate the mechanisms by which statins affect protein modification and cellular function.
• To inform strategies for improving the safety of statin therapy.

Main Methods:

• Literature review focusing on molecular and cellular mechanisms.
• Analysis of studies on protein prenylation, selenoprotein synthesis, and dolichol biosynthesis.
• Examination of research on mitochondrial dysfunction in statin-induced myopathy.

Main Results:

• Statins interfere with protein prenylation, a crucial post-translational modification.
• Statin use can impair selenoprotein synthesis and dolichol biosynthesis, affecting protein glycosylation.
• Mitochondrial dysfunction is implicated as a contributing factor to statin myopathy.

Conclusions:

• Statin-induced myopathy involves complex molecular disruptions, including interference with protein modification pathways.
• Understanding these mechanisms is key to identifying susceptible individuals and enhancing statin safety.
• Further research into statin's molecular effects will support expanded therapeutic applications.